If the data for any of the programs are good, I wouldn't be surprised if they partnered up with another biotech/pharma company looking to expand their portfolio to the CAR-T, CAR-NK space and are willing to pay an upfront free with milestone payments as it moves through development.
This would be an ideal de-risking - yes we lose the potential profits that may be generated, but at an early stage, this would provide confidence in the programs that are invested on.
I don't think the team will agree to a buyout and I don't think pharma will be focused on a buyout as CHM has multiple programs and does not work from a platform technology to generate their programs.
Ann: A$30 million Equity Placement Agreement with L1 Capital, page-29
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
-0.001(5.00%) |
Mkt cap ! $16.64M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.2¢ | 1.9¢ | $31.47K | 1.541M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1200682 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 12227 | 1 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| CHM (ASX) Chart |